New drug shows promise against superbug fungus in small trial

NCT ID NCT04148287

Completed Disease control Sponsor: Basilea Pharmaceutica Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 2 trial tested an experimental antifungal drug called APX001 (fosmanogepix) in 9 adults with blood or deep-organ infections caused by Candida auris, a fungus that often resists standard treatments. The drug was given by IV or mouth for up to 42 days. The goal was to see if the infection cleared and patients survived without needing other antifungals. Because the study was very small and had no placebo group, the results are encouraging but not conclusive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: APX001 (fosmanogepix), an antifungal drug given by IV or mouth
What this could lead to: If it works, this could offer a new treatment option for people with dangerous Candida auris infections that resist standard antifungals.
What could go wrong: This was a very small study (9 people) with no comparison group, so results are preliminary. The drug may not work as well in larger, more diverse groups, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANDIDA INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

candidemia candidiasis candidiasis, invasive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANDIDA INFECTION CANDIDEMIA INVASIVE CANDIDIASES

Contacts and locations

Locations

Milpark Academic Trauma Centre

Johannesburg, Gauteng, 2193, South Africa
Netcare Union Hospital Trauma Surgeons

Alberton, Gauteng, 1449, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.